TICKERNERD
Menu
CNMDCNMDHealthcare · Medical Devices

CNMD Stock Forecast: CONMED Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$54
+13.61% on the day

The 7 Wall Street analysts covering CONMED Corp. hold a median 12-month price target of $47 — -12.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 4 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
92/ 100
Median analyst target
$47
Analysts covering
7
Revenue$343.5M+0.3% y/y
Operating income$36.4M
Net income$23.1M
Free cash flow$34.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+17.3%
1M
+15.8%
YTD
+32.2%
1Y
+17.4%
From 52W high
0.0%
From 52W low
+67.1%
$32
$54
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CONMED Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
92/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Issuance
94
Revisions
87
Accruals
67
Volatility
64
Momentum
59
Quality
57
Growth
54
Size
38

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (54): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CNMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$35$40$45$50$55Jan 26Apr 26Jul 26Oct 26CNMDHigh $50Median $47Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
0 Buy6 Hold1 Sell
Low $43Median $47High $50

The green dot is the last close — the median target sits −12.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Oct 2026JP MorganMaintainsNeutral$45 → $50
29 Oct 2026Wells FargoMaintainsEqual-Weight$46 → $49
30 July 2026Piper SandlerReiteratesNeutral$39 → $45
30 July 2026Piper SandlerReiteratesNeutral—
30 July 2026Wells FargoMaintainsEqual-Weight$39 → $46
30 July 2026Wells FargoMaintainsEqual-Weight—
9 July 2026BMO CapitalInitiatesMarket Perform—
29 June 2026B of A SecuritiesDowngradeUnderperform—
18 May 2026B of A SecuritiesMaintainsNeutral—
1 May 2026Wells FargoMaintainsEqual-Weight—
30 Apr 2026JP MorganMaintainsNeutral—
17 Mar 2026Piper SandlerDowngradeNeutral—
29 Jan 2026NeedhamReiteratesHold—
29 Jan 2026Wells FargoMaintainsEqual-Weight—
8 Dec 2025B of A SecuritiesMaintainsNeutral—
6 Nov 2025JP MorganMaintainsNeutral—
6 Nov 2025Piper SandlerMaintainsOverweight—
6 Nov 2025Wells FargoMaintainsEqual-Weight—
31 July 2025Piper SandlerMaintainsOverweight—
12 June 2025NeedhamDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CNMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CNMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, CONMED Corp. returned +17.4% against +14.8% for the S&P 500, dividends included.

CNMD vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26CNMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+0.8%
Analysts raising
5
Analysts cutting
0
Fundamentals

CONMED Corp. (CNMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.3×

Cheaper than 39% of US stocks

Price / sales
1.2×

Cheaper than 68% of US stocks

Price / book
1.5×

Cheaper than 60% of US stocks

EV / EBITDA
11.0×

Cheaper than 37% of US stocks

Growth & margins
Revenue growth (YoY)
−0.7%

Higher than 27% of US stocks

Earnings growth (YoY)
592.4%

Higher than 96% of US stocks

Gross margin
57.5%

Higher than 70% of US stocks

Operating margin
9.6%

Higher than 63% of US stocks

Net margin
5.4%

Higher than 61% of US stocks

Returns & dividend
Return on equity
7.1%

Higher than 57% of US stocks

Return on assets
3.8%

Higher than 70% of US stocks

Dividend yield
1.5%

Higher than 77% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CONMED Corp. (CNMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CONMED Corp. has a market value of $1.6B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter shrank 0.7% year on year.

  • Net income over the same four quarters: $56.5M, a 4.1% net margin.

  • Diluted earnings per share, trailing twelve months: $1.85.

  • Free cash flow in the twelve months to 30 June 2026: $134.5M.

  • CONMED Corp. spent $12.4M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 30.1M.

  • Trailing P/E: 22.3×; forward P/E: 11.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.49%, paying out 0% of earnings.

  • CONMED Corp. employs 3,900 people — $352K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

CNMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CNMDCONMED Corp.$1.6B92
NVCRNovoCure Ltd.$1.7B97
BFLYButterfly Network, Inc.$1.8B89
ALMRAlamar Biosciences, Inc. (California)$1.9B2
INSPInspire Medical Systems, Inc.$1.9B88
ESTAEstablishment Labs Holdings, Inc.$1.9B74
ENOVEnovis Corp.$1.4B83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CONMED Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNMD news & analysis

CONMED Corporation to Participate in the Jefferies Global Healthcare Conference

Business Wire · 2 Nov 2026neutral

CONMED announced that it will participate in the Jefferies Global Healthcare Conference in London, with management scheduled for a fireside chat on November 16, 2026. A live audio webcast will be available through the Events section of the company's investor relations website.

Why it matters — The conference appearance and webcast provide CNMD watchers an opportunity to hear directly from management.

CONMED Q3 Earnings Call Highlights

MarketBeat · 29 Oct 2026positive

CONMED reported third-quarter 2026 revenue of $335.6 million and organic constant-currency sales growth of 6.7%. The company cited broad-based contributions from its general surgery and orthopedic surgery businesses.

Why it matters — The results provide CNMD watchers with an update on quarterly revenue growth and contributions across two business areas.

CONMED Corporation (CNMD) Q3 2026 Earnings Call Transcript

Seeking Alpha · 29 Oct 2026neutral

CONMED held its Q3 2026 earnings call on October 28, 2026. The excerpt identifies company executives and participating analysts but provides no earnings results or business commentary.

Why it matters — The call is a source of updates for CNMD watchers, but this excerpt contains no details about the company’s performance or outlook.

Conmed (CNMD) Q3 Earnings Top Estimates

Zacks Investment Research · 29 Oct 2026positive

Conmed reported quarterly earnings of $1.04 per share, above the Zacks Consensus Estimate of $1.00. Earnings were $1.08 per share a year earlier.

Why it matters — CNMD watchers may note that quarterly earnings exceeded the consensus estimate while coming in below the year-ago figure.

Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings

Zacks Investment Research · 29 Oct 2026neutral

The item says Conmed’s Q3 2026 top- and bottom-line results provide an overview of quarterly performance, and points readers to compare key metrics with Wall Street estimates and year-ago values. It does not provide specific metric results.

Why it matters — Those comparisons may give CNMD watchers additional context on quarterly performance beyond headline revenue and earnings figures.

FAQ

Frequently asked questions about CNMD stock

What is the CNMD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CONMED Corp. have a median 12-month price target of $47, with estimates ranging from $43 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNMD stock a buy right now?

Of the 7 analysts covering CONMED Corp., 0 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CONMED Corp. 92 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNMD?

As at 4 Nov 2026, CONMED Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will CNMD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -12.4% from the last close, and Ticker Nerd's factor model ranks CONMED Corp. 92 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNMD stock forecast for 2030?

No analyst covering CONMED Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $50 over the next 12 months.

How has CNMD stock performed over the past year?

CONMED Corp. returned +17.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CONMED Corp. do?

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and equipment used in hospitals, ambulatory surgery centers, and other clinical settings. The company’s portfolio supports minimally invasive procedures across orthopedic surgery, general surgery, gynecology, thoracic surgery, and gastroenterology.

What is the latest news on CNMD?

The most recent item we track (Business Wire, 2 Nov 2026): "CONMED Corporation to Participate in the Jefferies Global Healthcare Conference". CONMED announced that it will participate in the Jefferies Global Healthcare Conference in London, with management scheduled for a fireside chat on November 16, 2026. A live audio webcast will be available through the Events section of the company's investor relations website.

Company

About CONMED Corp.

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and equipment used in hospitals, ambulatory surgery centers, and other clinical settings. The company’s portfolio supports minimally invasive procedures across orthopedic surgery, general surgery, gynecology, thoracic surgery, and gastroenterology. Its products include surgical instruments, endoscopic technologies, electrosurgical systems, fixation devices, patient positioning solutions, and monitoring accessories designed to help healthcare professionals perform a wide range of procedures. CONMED Corporation serves medical providers in the United States and international markets, positioning itself as a specialist in operating-room technologies and procedural support tools. Based in Largo, Florida, CONMED Corporation focuses on products that are used throughout the surgical workflow, from access and visualization to treatment and patient care.

CEO Mr. Patrick J. Beyer · 3,900 employees · United States · https://www.conmed.com